Publications by authors named "David Morgans"

Claim this Profile
S
Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders.
Julie C Ullman, Kevin T Mellem, Yannan Xi, Vyas Ramanan, Hanne Merritt, David J Morgans

Sci Transl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The structural mechanism of human glycogen synthesis by the GYS1-GYG1 complex.
Nathan M Fastman, Yuxi Liu, Vyas Ramanan, Hanne Merritt, Eileen Ambing, David Morgans

Cell Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function.
Scott E Collibee, Gustave Bergnes, Chihyuan Chuang, Luke Ashcraft, Jeffrey Gardina, David Morgans

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of αβ and αβ reduces fibrogenesis in lung tissue explants from patients with IPF.
Martin L Decaris, Johanna R Schaub, Chun Chen, Jacob Cha, Gail G Lee, David J Morgans

Respir Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of , the First Direct Fast Skeletal Muscle Troponin Activator.
Scott E Collibee, Gustave Bergnes, Alexander Muci, William F Browne, Marc Garard, David J Morgans

ACS Med Chem Lett· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model.
Darren T Hwee, Adam Kennedy, Julie Ryans, Alan J Russell, Zhiheng Jia, David J Morgans

PLoS One· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tirasemtiv amplifies skeletal muscle response to nerve activation in humans.
Richard Hansen, Khalil G Saikali, Willis Chou, Alan J Russell, Michael M Chen, David J Morgans

Muscle Nerve· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension.
David Ho, Li Chen, Xin Zhao, Nicquanna Durham, Malar Pannirselvam, David J Morgans

PLoS One· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases.
Alan J Russell, James J Hartman, Aaron C Hinken, Alexander R Muci, Raja Kawas, David J Morgans

Nat Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.
Xin Zhao, David Ho, Patricio Abarzúa, Sunil K Dhar, Xi Wang, David J Morgans

J Pharmacol Exp Ther· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.
Fady I Malik, James J Hartman, Kathleen A Elias, Bradley P Morgan, Hector Rodriguez, David J Morgans

Science· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin.
Bradley P Morgan, Alexander Muci, Pu-Ping Lu, Xiangping Qian, Todd Tochimoto, David J Morgans

ACS Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.
You-Tang Shen, Fady I Malik, Xin Zhao, Christophe Depre, Sunil K Dhar, David J Morgans

Circ Heart Fail· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295.
Xiangping Qian, Andrew McDonald, Han-Jie Zhou, Nicholas D Adams, Cynthia A Parrish, David J Morgans

ACS Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.
Kenneth W Wood, Latesh Lad, Lusong Luo, Xiangping Qian, Steven D Knight, David J Morgans

Proc Natl Acad Sci U S A· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective killing of the human pathogen Candida albicans by a specific inhibitor of non-essential mitotic kinesin Kip1p.
Penelope R Chua, David M Roof, Yan Lee, Roman Sakowicz, David Clarke, David Morgans

Mol Microbiol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombophilia screening and adverse pregnancy outcomes associated with uteroplacental insufficiency.
David Morgans

Med J Aust· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis